JP2008513354A - 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用 - Google Patents

慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用 Download PDF

Info

Publication number
JP2008513354A
JP2008513354A JP2007522632A JP2007522632A JP2008513354A JP 2008513354 A JP2008513354 A JP 2008513354A JP 2007522632 A JP2007522632 A JP 2007522632A JP 2007522632 A JP2007522632 A JP 2007522632A JP 2008513354 A JP2008513354 A JP 2008513354A
Authority
JP
Japan
Prior art keywords
cells
antibody
cancer
administered
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007522632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513354A5 (https=
Inventor
キャサリン エス． バウディッシュ，
アンケ クレッツ−ロメル，
ジョン マクワーター，
俊昭 丸山
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/894,672 external-priority patent/US9249229B2/en
Priority claimed from US10/996,316 external-priority patent/US7408041B2/en
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2008513354A publication Critical patent/JP2008513354A/ja
Publication of JP2008513354A5 publication Critical patent/JP2008513354A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007522632A 2004-07-20 2005-07-19 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用 Withdrawn JP2008513354A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/894,672 US9249229B2 (en) 2000-12-08 2004-07-20 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US10/996,316 US7408041B2 (en) 2000-12-08 2004-11-23 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US11/171,567 US20060057651A1 (en) 2000-12-08 2005-06-30 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
PCT/US2005/025488 WO2006020266A2 (en) 2004-07-20 2005-07-19 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012053212A Division JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Publications (2)

Publication Number Publication Date
JP2008513354A true JP2008513354A (ja) 2008-05-01
JP2008513354A5 JP2008513354A5 (https=) 2008-08-14

Family

ID=35907987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007522632A Withdrawn JP2008513354A (ja) 2004-07-20 2005-07-19 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用
JP2012053212A Expired - Fee Related JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012053212A Expired - Fee Related JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Country Status (8)

Country Link
US (4) US20060057651A1 (https=)
EP (2) EP2441777B1 (https=)
JP (2) JP2008513354A (https=)
AU (1) AU2005274785B2 (https=)
CA (1) CA2574488C (https=)
DK (1) DK2441777T3 (https=)
ES (1) ES2569240T3 (https=)
WO (1) WO2006020266A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516494A (ja) * 2010-01-11 2013-05-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
JP2013519682A (ja) * 2010-02-11 2013-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を使用する治療方法
JP2015524399A (ja) * 2012-07-18 2015-08-24 シャンハイ バーディー バイオテック インコーポレイテッド 標的免疫療法のための化合物
JP2021073169A (ja) * 2015-12-16 2021-05-13 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2008089022A2 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
DK2164514T3 (en) * 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
AU2016228280B2 (en) * 2007-07-12 2019-02-21 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2009014745A1 (en) * 2007-07-25 2009-01-29 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
US8206897B2 (en) * 2008-04-04 2012-06-26 Trillium Therapeutics Inc. Assay for soluble CD200
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
ES2785349T3 (es) 2011-06-10 2020-10-06 Canada Minister Nat Defence Anticuerpos anti-ricina y sus usos
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2764123B1 (en) 2011-10-05 2019-01-16 Dharmacon, Inc. Optimization of vectors for effective delivery and expression of genetic content
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US20190048055A1 (en) * 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
CN109239334A (zh) * 2018-09-10 2019-01-18 吉林大学 建立时间分辨荧光免疫层析法检测MxA试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109633142B (zh) * 2018-12-22 2021-08-27 中国人民解放军第四军医大学 一种急性髓细胞性白血病诊断模型的建立方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0246297A (ja) * 1988-08-08 1990-02-15 Takeda Chem Ind Ltd モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法
JP2001522867A (ja) * 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
WO2002059280A2 (en) * 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
ATE68703T1 (de) 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
CA2580812A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US5728815A (en) 1992-03-30 1998-03-17 Board Of Regents, The University Of Texas System Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AU7503296A (en) 1995-10-31 1997-05-22 University Of Alabama At Birmingham Research Foundation, The Genetic induction of receptors for targeted radiotherapy
AU1144097A (en) 1995-12-08 1997-07-03 Brigham And Women's Hospital Ox-2 costimulatory molecule
EP0892643B2 (en) 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020192215A1 (en) 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
WO2001068697A2 (en) 2000-03-17 2001-09-20 Gorczynski Reginald M Methods and compositions for immunoregulation
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
CA2417874C (en) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Use of ox-2 inhibitors for the treatment of cancer
US20030017491A1 (en) 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
ATE406385T1 (de) 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2448668A1 (en) * 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
CA2460639C (en) 2001-09-19 2013-07-16 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003299823A1 (en) 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
EP1606387A4 (en) 2003-03-04 2008-04-23 Alexion Pharma Inc VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
JP2007518827A (ja) 2004-02-02 2007-07-12 シェーリング　コーポレイション Ｃｄ２００およびｃｄ２００ｒを調節する方法
AU2005249540B2 (en) 2004-06-02 2009-02-19 Sidney Kimmel Cancer Center Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
CN101627054A (zh) * 2005-07-11 2010-01-13 马克罗基因公司 用人源化抗cd16a抗体治疗自身免疫疾病的方法
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0246297A (ja) * 1988-08-08 1990-02-15 Takeda Chem Ind Ltd モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法
JP2001522867A (ja) * 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
WO2002059280A2 (en) * 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6011059575; 山口俊晴　外１１名: '癌のターゲティング療法の進歩　『モノクローナル抗体を利用した癌ミサイル療法のＤＤＳ』' 日本臨床 Ｖｏｌ．５６，Ｎｏ．３, 199803, Ｐ．６３８-６４３ *
JPN6011059577; 山口俊晴　外３名: '臨床応用　治療　『腫瘍マーカーを利用した免疫ミサイル療法』' 日本臨床 Ｖｏｌ．５４，Ｎｏ．６, 199606, Ｐ．１６７４-１６７９ *
JPN6011059578; 山口俊晴　外４名: '特集　ＢＲＭとＢｉｏｍｅｄｉｃａｌ　Ｍｏｄｕｌａｔｉｏｎ　『ＢＲＭとミサイル療法』' Ｂｉｏｔｈｅｒａｐｙ Ｖｏｌ．１０，Ｎｏ．４，Ｐ．６０５-６０９, 199604, Ｐ．６０５-６０９ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516494A (ja) * 2010-01-11 2013-05-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
JP2013519682A (ja) * 2010-02-11 2013-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を使用する治療方法
JP2015524399A (ja) * 2012-07-18 2015-08-24 シャンハイ バーディー バイオテック インコーポレイテッド 標的免疫療法のための化合物
JP2020007346A (ja) * 2012-07-18 2020-01-16 シャンハイ バーディー バイオテック インコーポレイテッド 標的免疫療法のための化合物
JP7062298B2 (ja) 2012-07-18 2022-05-06 バーディー バイオファーマシューティカルズ インコーポレイテッド 標的免疫療法のための化合物
JP2021073169A (ja) * 2015-12-16 2021-05-13 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害

Also Published As

Publication number Publication date
EP1786464A4 (en) 2009-09-02
CA2574488A1 (en) 2006-02-23
DK2441777T3 (en) 2016-05-17
EP2441777A3 (en) 2012-07-25
US20060057651A1 (en) 2006-03-16
US8999328B2 (en) 2015-04-07
US7915000B2 (en) 2011-03-29
EP1786464A2 (en) 2007-05-23
WO2006020266A2 (en) 2006-02-23
EP2441777A2 (en) 2012-04-18
WO2006020266A3 (en) 2009-03-12
JP5727406B2 (ja) 2015-06-03
EP2441777B1 (en) 2016-02-17
US20110236387A1 (en) 2011-09-29
JP2012111780A (ja) 2012-06-14
AU2005274785B2 (en) 2012-05-03
CA2574488C (en) 2016-11-15
ES2569240T3 (es) 2016-05-09
US20150368341A1 (en) 2015-12-24
AU2005274785A1 (en) 2006-02-23
US20090074759A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
JP5727406B2 (ja) 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用
US9150661B2 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US8840885B2 (en) Methods for treating chronic lymphocytic leukemia
US20040198661A1 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2012211347B9 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
HK1168604A (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2787818C (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2777686A1 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130218

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130301